A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction, With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Canagliflozin (Primary)
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Dec 2015 Primary endpoint (Change in mean 24-hour systolic blood pressure (SBP) by Ambulatory Blood Pressure Monitoring (ABPM) has been met as per results published in the Journal of Clinical Hypertension (Greenwich).
- 10 Dec 2015 Results published in the Journal of Clinical Hypertension (Greenwich)
- 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov